Drug Trial Radar · NCT06862791
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
377
Actual
Start
Feb 18, 2025
Primary completion
May 11, 2026
Study completion May 11, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or overweight with at least one weight-related co-morbidity.
Conditions
- Obesity or Overweight
Interventions
AZD9550Drug
IMP injected subcutaneous, once weekly. Unit dose strength as per CSP
AZD6234Drug
IMP injected subcutaneous, once weekly. Unit dose strength as per CSP.
Placebo comparatorDrug
Placebo matching IMP dose injected subcutaneously, once weekly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in body weight from baseline after 36 weeks of treatmentTime frame: 36 weeks
- Weight loss ≥ 5% from baseline after 36 weeks of treatmentTime frame: 36 weeks
Locations
53 sites in 5 countries. Site status is shown where the registry gives one.
Research Site
Dothan, Alabama
Research Site
Vestavia Hills, Alabama
Research Site
Cerritos, California
Research Site
Escondido, California
Research Site
Huntington Park, California
Research Site
Lincoln, California
Research Site
Sacramento, California
Research Site
Waterbury, Connecticut
Research Site
Palm Harbor, Florida
Research Site
Decatur, Georgia
Research Site
Stockbridge, Georgia
Research Site
Champaign, Illinois
Research Site
South Bend, Indiana
Research Site
Valparaiso, Indiana
Research Site
Sioux City, Iowa
Research Site
Southfield, Michigan
Research Site
Missoula, Montana
Research Site
Omaha, Nebraska
Research Site
Albuquerque, New Mexico
Research Site
Fargo, North Dakota
Research Site
Cincinnati, Ohio
Research Site
Columbus, Ohio
Research Site
Tulsa, Oklahoma
Research Site
Medford, Oregon
Research Site
Kingsport, Tennessee
Research Site
Brownsville, Texas
Research Site
Houston, Texas
Research Site
Arlington, Virginia
Research Site
Renton, Washington
Research Site
Maroochydore, Australia
Research Site
Maroubra, Australia
Research Site
Norwood, Australia
Research Site
St Albans, Australia
Research Site
St Leonards, Australia
Research Site
Calgary, Alberta, Canada
Research Site
Surrey, British Columbia, Canada
Research Site
Guelph, Ontario, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Sarnia, Ontario, Canada
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.